Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EBP | Q15125 | 8/20 | 0.55 |
| ▸ | NPC1L1 | Q9UHC9 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.41 |
| ▸ | HMGCR | P04035 | 1/20 | 0.39 |
| ▸ | INPP5D | Q92835 | 1/20 | 0.37 |
| ▸ | CDC25A | P30304 | 3/20 | 0.37 |
| ▸ | CDC25B | P30305 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17487215 | 1.00 | EBP (0.55) | EBPNPC1L1MEN1USP2KMT2A | |
| SCHEMBL18714858 | 1.00 | EBP (0.55) | EBPNPC1L1MEN1USP2KMT2A | |
| SCHEMBL18714859 | 1.00 | EBP (0.55) | EBPNPC1L1MEN1USP2KMT2A | |
| SCHEMBL18199154 | 0.81 | EBP (0.52) | EBPNPC1L1MEN1USP2KMT2A | |
| SCHEMBL13185816 | 0.75 | EBP (0.55) | EBPNPC1L1MEN1USP2KMT2A | |
| Pollinastanol SCHEMBL29423016 | 0.70 | ACLY (0.49) | EBPNPC1L1MEN1USP2KMT2A | |
| SCHEMBL133391 | 0.67 | EBP (0.50) | EBPNPC1L1MEN1USP2KMT2A | |
| SCHEMBL30652952 | 0.66 | EBP (0.41) | EBPNPC1L1MEN1USP2KMT2A | |
| Cycloartanol SCHEMBL455050 | 0.66 | ACLY (0.67) | EBPHMGCRCDC25ACDC25B | |
| Cycloartanol SCHEMBL13324286 | 0.66 | ACLY (0.67) | EBPHMGCRCDC25ACDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9611270-B2 | Inhibitors of CYP17A1 | UNIVERSITY OF KANSAS (US) | 2017-04-04 | — | — | US | disclosed |
| US-20160031929-A1 | INHIBITORS OF CYP17A1 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031929-A1 | INHIBITORS OF CYP17A1 | CYP19A1, CYP17A1, CYP21A2 | EBP 568/4885NPC1L1 1525/4885MEN1 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.